Bio-Rad Reports Second-Quarter 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bio-Rad Reports Second-Quarter 2014 Financial Results

HERCULES, CA--(Marketwired - Aug 5, 2014) - Bio-Rad Laboratories, Inc. ( NYSE : BIO ) and ( NYSE : BIO.B ), a global provider of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2014.

Second-quarter reported revenues were $536.8 million, up 2.2 percent compared to $525.3 million reported for the second quarter of 2013. On a currency-neutral basis, quarterly revenues increased 1.1 percent compared to the same period last year. Second-quarter gross margin was 55.4 percent compared to 57.1 percent reported during the same quarter in 2013. The net decline in gross margin is largely attributable to product mix and continued pricing pressures in the diagnostics market. 

Net income for the second quarter of 2014 was $31.6 million, or $1.09 per share on a fully diluted basis, compared to $34.6 million, or $1.20 per share, respectively, during the same period last year.

On a reported basis, year-to-date revenues were up 2.1 percent to $1.05 billion compared to $1.02 billion for the first two quarters of 2013. On a currency-neutral basis, revenues grew 2.0 percent. 

Year-to-date net income for 2014 was $38.3 million, or $1.32 per share on a fully diluted basis, compared to $54.8 million, or $1.90 per share, respectively, during the same period in 2013.

The lower net income for the first half of 2014 when compared to the same period last year, was primarily driven by lower gross margins, higher SG&A that includes a $9.8 million accrual in the first quarter resulting from the Company's efforts to resolve the previously disclosed investigation of the Company in connection with the United States Foreign Corrupt Practices Act, and an increase in R&D expense as a result of our current quarter acquisition of GnuBIO, Inc. In contrast to the first half of 2013, the tax rate for the first six months of 2014 is higher as it did not include a benefit of the U.S. research & development tax credit. Cash flow was strong for the six months ended June 30, 2014 compared to the same period last year, as cash provided by operations was $149.8 million in 2014 versus $43.8 million last year. This strength was largely due to an increase in customer collections, as well as a decrease in interest paid in the first half of 2014 related to the redemption of Senior Subordinated Notes in 2013.

"Although we continued to see softness in some markets during the second quarter, we are encouraged by an increase in sales in many parts of the world," said Norman Schwartz, Bio-Rad Chief Executive Officer. "As the year continues, we will remain focused on new products and systems that will help us grow our business."

Life Science Life Science segment net sales for the second quarter of 2014 were $170.3 million, essentially flat, when compared to the same period last year. On a currency-neutral basis, Life Science segment net sales decreased by 1.1 percent compared to the same quarter last year. Although sales increased in both Europe and the U.S. during the second quarter of 2014, the timing of orders in Asia, most notably in China, had a negative impact on results compared to the second quarter of 2013. This performance was somewhat offset by growth of the Company's Droplet Digital™ PCR, process chromatography, and cell biology products.

Clinical Diagnostics Reported net sales for the Clinical Diagnostics segment in the second quarter of 2014 were $362.9 million, up 3.2 percent compared to the same quarter last year. On a currency-neutral basis, net sales increased 2.1 percent. While sales increased in China and emerging markets in the second quarter of 2014, this was partially offset by a decline in Europe. During the quarter, Bio-Rad announced the launch of two new kits for its fully-automated BioPlex ® 2200 system: the BioPlex ® HIVAg-Ab kit, a first-in-class 5 th generation HIV test, and the BioPlex ® Vitamin D kit. Both kits were launched in markets outside the U.S.  

Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) August 5, 2014. Interested parties may access the call by dialing 866-318-8617 (in the U.S.) or 617-399-5136 (international), passcode: 33283045.

A live webcast of the conference call may be accessed in the Investor Relations section of www.bio-rad.com . A replay of the call will be available at 888-286-8010 (in the U.S.) or 617-801-6888 (international), passcode: 48074970, for seven days following the call. The webcast of the call will be archived on the Bio-Rad site and may be accessed in the Investor Relations section.

About Bio-Rad Bio-Rad Laboratories, Inc. ( NYSE : BIO ) and ( NYSE : BIO.B ) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,750 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com .

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

   
Bio-Rad Laboratories, Inc.  
Condensed Consolidated Statements of Income  
                       
(in thousands, except per share data)  
(UNAUDITED)  
                       
                       
                       
                       
  Three Months Ended June 30,     Six Months Ended June 30,  
  2014     2013     2014     2013  
Net sales $ 536,832     $ 525,321     $ 1,046,176     $ 1,024,993  
  Cost of goods sold   239,590       225,220       473,645       453,480  
Gross profit   297,242       300,101       572,531       571,513  
                               
  Selling, general and administrative expense   195,838       195,331       398,113       381,248  
  Research and development expense   55,717       51,841       108,260       102,184  
Income from operations   45,687       52,929       66,158       88,081  
                               
  Interest expense   5,564       11,664       9,421       22,641  
  Foreign currency exchange (gains) losses, net   (286 )     865       2,451       2,393  
  Other (income) expense, net   (8,388 )     (8,644 )     (9,049 )     (10,044 )
Income before income taxes   48,797       49,044       63,335       73,091  
                               
  Provision for income taxes   (17,166 )     (14,442 )     (25,036 )     (18,317 )
Net income including noncontrolling interests   31,631       34,602       38,299       54,774  
                               
  Net income attributable to noncontrolling interests   -       -       -       (21 )
Net income attributable to Bio-Rad $ 31,631     $ 34,602     $ 38,299     $ 54,753  
                               
Basic earnings per share:                              
  Net income per basic share attributable to Bio-Rad $ 1.10     $ 1.21     $ 1.33     $ 1.92  
                               
  Weighted average common shares - basic   28,826       28,538       28,809       28,516  
                               
Diluted earnings per share:                              
  Net income per diluted share attributable to Bio-Rad $ 1.09     $ 1.20     $ 1.32     $ 1.90  
                               
  Weighted average common shares - diluted   29,092       28,868       29,076       28,843  
                                 
                                 
                                 
Bio-Rad Laboratories, Inc.
Condensed Consolidated Balance Sheets
 
(In thousands)
       
       
       
       
  June 30,   December 31,
  2014   2013
  (UNAUDITED)    
Current assets:          
  Cash and cash equivalents $ 384,670   $ 331,551
  Short-term investments   262,908     277,369
  Accounts receivable, net   378,891     422,660
  Inventories, net   520,642     501,291
  Other current assets   220,383     214,985
    Total current assets   1,767,494     1,747,856
           
Property, plant and equipment, net   440,326     429,355
Goodwill, net   535,223     517,770
Purchased intangibles, net   292,547     266,188
Other assets   432,161     427,621
    Total assets $ 3,467,751   $ 3,388,790
           
           
Current liabilities:          
  Accounts payable $ 125,461   $ 148,510
  Accrued payroll and employee benefits   134,905     130,658
  Notes payable and current maturities of long-term debt   1,725     1,786
  Income taxes payable and deferred tax liabilities   28,264     20,948
  Other current liabilities   189,893     185,570
    Total current liabilities   480,248     487,472
           
Long-term debt, net of current maturities   435,607     435,615
Other long-term liabilities   301,952     278,981
    Total liabilities   1,217,807     1,202,068
           
    Total stockholders' equity   2,249,944     2,186,722
    Total liabilities and stockholders' equity $ 3,467,751   $ 3,388,790
               
               
               
Bio-Rad Laboratories, Inc.  
Condensed Consolidated Statements of Cash Flows  
   
(In thousands)  
(UNAUDITED)  
           
           
           
           
  Six Months Ended June 30,  
  2014     2013  
               
Cash flows from operating activities:              
  Cash received from customers $ 1,087,487     $ 1,006,345  
  Cash paid to suppliers and employees   (918,152 )     (911,227 )
  Interest paid   (10,912 )     (24,681 )
  Income tax payments   (17,059 )     (42,102 )
  Other operating activities   8,460       15,419  
  Net cash provided by operating activities   149,824       43,754  
               
Cash flows from investing activities:              
  Payments for acquisitions and long-term investments   (42,010 )     (65,883 )
  Other investing activities   (59,928 )     (68,683 )
  Net cash used in investing activities   (101,938 )     (134,566 )
               
Cash flows from financing activities:              
  Payments on long-term borrowings   (118 )     (123 )
  Other financing activities   6,416       (6,013 )
  Net cash provided by (used in) financing activities   6,298       (6,136 )
               
Effect of foreign exchange rate changes on cash   (1,065 )     559  
               
Net increase (decrease) in cash and cash equivalents   53,119       (96,389 )
Cash and cash equivalents at beginning of period   331,551       463,388  
Cash and cash equivalents at end of period $ 384,670     $ 366,999  
               
               
Reconciliation of net income including noncontrolling interests to net cash provided by operating activities:              
               
Net income including noncontrolling interests $ 38,299     $ 54,774  
Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:              
  Depreciation and amortization   73,007       68,211  
  Changes in working capital   38,045       (90,568 )
  Other   473       11,337  
Net cash provided by operating activities $ 149,824     $ 43,754  
               

Investor and Financial Contacts: Bio-Rad Laboratories, Inc. Christine Tsingos Executive Vice President and Chief Financial Officer Ron Hutton Vice President, Treasurer 510-724-7000 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 84

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 46

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Cruise Line Celebrates Employees as Godparents of Treasure

Updated Category News Views 97

Disney Cruise Line Celebrates Employees in Honor of Disney Treasure Disney Cruise Line is redefining maritime traditions in a beautiful manner by honoring its dedicated employees worldwide. The company’s latest announcement revealed that the honorific role of "godparent" for the new ship, the Disney Treasure, will be shared among its tremendous cast, crew, Imagineers,...

Continue Reading
Regional Management Corp. to Share Q3 2024 Financial Insights

Updated Category News Views 79

Regional Management Corp. to Announce Q3 Results Greenville, S.C. – Regional Management Corp. (NYSE: RM), a prominent player in the consumer finance sector, is set to share its financial results for the third quarter of 2024. Conference Call Details and Replay The company will report its quarterly results after market close, providing investors and stakeholders with...

Continue Reading
Suvoda Recognized as a Leader in Clinical Trial Technology

Updated Category News Views 147

Suvoda Acknowledged as a Leader in RTSM Technology Suvoda, a cutting-edge clinical trial technology company, recently shared exciting news about their IRT (Interactive Response Technology) software, which has been designated as a Leader in the prominent Everest Group's PEAK Matrix assessment for RTSM (Randomization and Trial Supply Management) technology. This recognition...

Continue Reading
Cereno Scientific Expands CS014 Focus to Combat PH-ILD

Updated Category News Views 131

Cereno Scientific Expands CS014 Focus to Combat PH-ILD Cereno Scientific, a pioneering biotech company, has made a significant announcement regarding the development focus of its HDAC inhibitor CS014. This innovative treatment is now targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD), an area marked by a high level of unmet medical need....

Continue Reading
Dysmenorrhea Treatment Market Growth Insights for 2032

Updated Category News Views 188

Global Dysmenorrhea Treatment Market Insights Dysmenorrhea, commonly referred to as menstrual cramps, affects many women globally, causing significant discomfort during their menstrual cycles. Recent trends indicate that as awareness of this condition grows, so does the demand for effective treatments. The global dysmenorrhea treatment market is projected to surpass USD 8...

Continue Reading